Navigation Links
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Date:10/12/2009

00 million for the exclusive rights to commercialize the oral tablet, which is already approved in the US, in the territory of the US and Canada, as well as to develop and commercialize a depot formulation of Fanapt for patients in this territory. Vanda will be eligible for additional payments upon achieving defined development and commercial milestones and will also receive sales royalties. Vanda will retain rights to develop and commercialize Fanapt outside the territory of US and Canada, but Novartis has the option to enter into discussions with Vanda to co-commercialize Fanapt or receive sales royalties outside this territory. The consummation of the transaction is subject to the receipt of customary regulatory approvals, which are expected by the end of 2009.

Important Safety Information

Fanapt is indicated for the acute treatment of schizophrenia in adults.

Increased Mortality: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo. Fanapt is not approved for the treatment of patients with dementia-related psychosis.

QT Prolongation: In an open-label QTc study in patients with schizophrenia or schizoaffective disorder (N=160), Fanapt was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily. This affect was augmented by the presence of CYP450, 2D6 or 3A4 metabolic inhibition. The use of Fanapt should be avoided in combination with other drugs that are known to prolong QTc. Caution is warranted when prescribing Fanapt with drugs that inhibit Fanapt metabolism.

Neuroleptic Malignant Syndrome (NMS):A potentially fatal symptom complex, has been reported in association with administration of antipsychotic drugs. Clinical manifestations include hyperpyrexia, muscle rigidity, altered mental sta
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
2. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
3. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
4. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
7. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
8. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
9. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
10. Orion Genomics Enters Discovery Collaboration and License Agreement to Advance Personalized Diagnostics
11. Elbit Imaging Ltd. Announces Sale of Plaza Centers Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... Alemania, 6 de marzo de 2015 ... de gestión empresarial de imagen médica, fortalece su ... nombramiento de Randolph Sternberg como director ... como director de operaciones. Logo - ... será responsable de las ventas y desarrollo ...
(Date:3/6/2015)... , March 6, 2015 Lucerne ... Trademark Office,s publication of U.S. Patent Application No. ... ,249 Patent Application features claimed methods of "informing ... used to treat Binge Eating Disorder (,BED,)," including ... or "flyer or an advertisement," as well as ...
(Date:3/6/2015)... -- UNICANCER pourra identifier plus ... de l,innovation thérapeutique.   TEMIS ... pour l,Entreprise, annonce que sa solution Luxid® a ... lutte contre le cancer (CLCC), comme module sémantique ... Soin-Recherche) conduit par la société de conseil et ...
Breaking Medicine Technology:TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3Lucerne Biosciences Announces Publication of Claimed Methods for Treating Binge Eating Disorder with Lisdexamfetamine Dimesylate 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 2TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 3TEMIS et SWORD accompagnent UNICANCER pour accélérer la recherche par l'analyse sémantique des dossiers patients 4
... Jan. 20, 2011 TheCarrot.com , a ... engagement programs, announced the immediate availability of its ... of the University of California at San Francisco,s ... proven behavior modification methodology with TheCarrot.com,s award-winning online ...
... SYK ) announced today that it has been named ... in the magazine,s 14th annual survey of top-rated workplaces in the ... the list, and the company was ranked 68th out of 100; ... related stories will appear in the February 7 issue of FORTUNE, ...
Cached Medicine Technology:TheCarrot.com Launches Quit Smoking Program 2TheCarrot.com Launches Quit Smoking Program 3Stryker Corporation Named One of FORTUNE Magazine's '100 Best Companies to Work For' 2
(Date:3/6/2015)... OR (PRWEB) March 06, 2015 Ticket Down ... in Portland, Oregon at the Moda Center. After ... superstar Garth Brooks is showing no signs of letting up ... the country legend and his wife, Trisha Yearwood, to venues ... would be bringing their critically acclaimed tour to the Moda ...
(Date:3/6/2015)... 06, 2015 As the Muscular Dystrophy ... programs, the organization has hired two new Scientific Program ... They will report to Grace Pavlath, Ph.D, who joined ... Scientific Program Director, and together will lead MDA as ... and cures for various types of neuromuscular and motor ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 US Sports ... three Maryland camps – two non-contact specialty camps and ... run by Perfect Performance Training, located at Bowie State ... on developing position specific skills, speed and strength of ... at Salisbury University with Marvin Graves, former quarterback in ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
(Date:3/6/2015)... GA (PRWEB) March 06, 2015 ... announced the release of a Clostridium Difficile (C ... providers. The C Diff use case is the ... that span hospital acquired infections, chronic conditions, and ... platform, the C Diff solution flags at risk ...
Breaking Medicine News(10 mins):Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 2Health News:Garth Brooks Tickets in Portland, OR at the Moda Center: Ticket Down Slashes Garth Brooks Ticket Prices at the Moda Center in Portland 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Jvion Predicts Patients at Risk of C Difficile Infection to Reduce Risk and Save Lives 2
... Nutraceutical,International Corporation (Nasdaq: NUTR ) today reported ... 30, 2008. , Net ... compared,to $39.9 million for the same quarter of fiscal 2007. ... $1.5 million, or $0.14 diluted earnings per,share, compared to net ...
... STAAR Surgical Company,(Nasdaq: STAA ) ... leading ophthalmic,surgeons, CAST (Collamer(R) Accommodating Study Team), to ... evaluating the accommodative properties,of its Collamer lens technology. ... restore the eye,s ability to "accommodate," or,to adjust ...
... NORTHFIELD, Ill., Nov. 20 The College of ... pleased to announce it has awarded the CAP ... This accreditation is based on the International ... and continual quality management and focuses on improved ...
... Does your pet misbehave when,you leave the house? ... in schedule can negatively affect your pet,s behavior.,Recent research ... United States,suffer from separation anxiety, resulting in inappropriate, unwanted,behaviors. ... http://www.newscom.com/cgi-bin/prnh/20081120/NYFNSR09 ) , ...
... for an easy,fun and inexpensive way to stay fit ... Kideosyncrasy Vol.2 ( www.kideosyncrasy.com ) is a fun tool ... is jam-packed with live-action;,kids-teaching-kids how to easily step into ... tips on nutrition and exercise, Kideosyncrasy,promotes health and fitness ...
... laser hair removal on the face, underarms, back, bikini area, ... ... -- With laser technology, beauty has become high tech. No longer a ... the medi-spa, offering a range of cosmetic options, including permanent hair ...
Cached Medicine News:Health News:Nutraceutical Reports 2008 Fiscal Year End Results 2Health News:Nutraceutical Reports 2008 Fiscal Year End Results 3Health News:Nutraceutical Reports 2008 Fiscal Year End Results 4Health News:Nutraceutical Reports 2008 Fiscal Year End Results 5Health News:Nutraceutical Reports 2008 Fiscal Year End Results 6Health News:Nutraceutical Reports 2008 Fiscal Year End Results 7Health News:STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses 2Health News:STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses 3Health News:STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses 4Health News:STAAR Surgical Forms Team of Leading Ophthalmic Surgeons to Study the Use of Collamer(R) Material for Accommodating Intraocular Lenses 5Health News:Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab 2Health News:Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab 3Health News:A Happy Pet for the Holidays: Natural Remedies to Treat Animals' Complex Emotions 2Health News:Give Kids the Gift of Fun and Fitness This Holiday Season 2Health News:Laser Beam Beauty: 'The Complete Guide to Laser Hair Removal' DVD released by Aesthetic VideoSource 2
... FingerPrint Sleep Hand-Held Pulse Oximeter with ... for sleep screening studies in the ... With its easy-to-use, 2-key operation, ... measurements of SpO 2 , pulse ...
... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
... Administration (FDA) has granted approval of Alcon's ... patients with and without presbyopia. This innovative ... to give patients a full range of ... greatly increases their independence from glasses after ...
Engineered for high volume surgical efficiencies, the Bausch & Lomb Hansatome Microkeratome, a corneal resection instrument, features an automated pivoting motion that provides smooth, resistance-fre...
Medicine Products: